Why the study?
Does cardiac-specific expression of activated GSK-3 beta suppress cardiac hypertrophy in vivo in response to pathologic stimuli?
Does cardiac-specific expression of activated GSK-3 beta suppress cardiac hypertrophy in vivo in response to pathologic stimuli?
In vivo activation of GSK-3 beta suppresses pathologic cardiac hypertrophy, identifying it as a potential therapeutic target for preventing heart failure.
No takes yet. Share an insight, caveat, or question.
Supports GSK-3β activation to limit hypertrophy in mice; leaves open clinical translation for heart failure prevention.
Antos et al. (2002) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: